Cosmaceutical Research Laboratory Inc
FDA inspection history in Surrey, Canada, 2020 to 2024
- 1
- Form 483
- 1
- Close-out
Every document, by year
- Form 483
- Close-out
2020: one close-out letter; 2024: one Form 483.
The story so far
Built from the dates and citations on the documents themselves.
- 2020One close-out letter, at Surrey, Canada.
- 2024One Form 483, at Surrey, Canada.
Cited most
Across all Cosmaceutical Research Laboratory observations on file
- 21 CFR 211.110(a)Sampling and testing of in-process materials and drug products1
- 21 CFR 211.160(b)General requirements1
- 21 CFR 211.192Production record review1
- 21 CFR 211.22(d)Responsibilities of quality control unit1
- 21 CFR 211.67(a)Equipment cleaning and maintenance1
The complete Cosmaceutical Research Laboratory file.
All 2 documents as original PDFs, in one order. For supplier audits, diligence and inspection prep.
The price of the documents, added to your cart together
Sites
Surrey, Canada
One Form 483 and one close-out letter · 2020 to 2024 · 5 observations
Latest: Form 483, Oct 12, 2024 →
Documents
2 on file, newest first| Date | Document | Location | Observations | Price |
|---|---|---|---|---|
| 2024-10-12 | 483 Form 483 | Surrey, Canada | 5 | $99 |
| 2020-05-29 | Close-out Close-out letter | Surrey, Canada | — | $99 |
Investigators on these documents
FEI number 3003878590 · most recent document Oct 12, 2024
About Cosmaceutical Research Laboratory Inc
How many FDA Form 483s has Cosmaceutical Research Laboratory Inc received?
FDA Intel has 1 Form 483 on file for Cosmaceutical Research Laboratory Inc; the most recent is dated Oct 12, 2024.
When was Cosmaceutical Research Laboratory Inc last inspected by FDA?
The most recent FDA inspection document on file for Cosmaceutical Research Laboratory Inc is a Form 483 dated Oct 12, 2024, for the site in Surrey, Canada.
What did FDA cite at Cosmaceutical Research Laboratory Inc?
The regulations cited most in the observations on file for Cosmaceutical Research Laboratory Inc are 21 CFR 211.110(a) (Sampling and testing of in-process materials and drug products), 1 time; 21 CFR 211.160(b) (General requirements), 1 time; 21 CFR 211.192 (Production record review), 1 time.